Designed transcription activator-like effector proteins efficiently induced the expression of latent HIV-1 in latently infected cells

AIDS Research and Human Retroviruses

Volumn 31, Issue 1, 2015, Pages 98-106

  Wang, Xiaohui ^a   Wang, Pengfei ^a   Fu, Zheng ^a   Ji, Haiyan ^a   Qu, Xiying ^a   Zeng, Hanxian ^a   Zhu, Xiaoli ^a   Deng, Junxiao ^a   Lu, Panpan ^a   Zha, Shijun ^a   Song, Zhishuo ^a   Zhu, Huanzhang ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN; TRANSCRIPTION ACTIVATOR LIKE EFFECTOR PROTEIN; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; GREEN FLUORESCENT PROTEIN; HYBRID PROTEIN;

ARTICLE; CELL CYCLE; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DNA SEQUENCE; EXPRESSION VECTOR; FEMALE; GENE; GENE EXPRESSION; GENETIC ENGINEERING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LATENT PERIOD; PRIORITY JOURNAL; PROMOTER REGION; PROVIRUS; TALE GENE; VIRUS EXPRESSION; VIRUS REACTIVATION; BIOSYNTHESIS; CELL LINE; DRUG EFFECTS; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERMINAL REPEAT; METABOLISM; MOLECULAR GENETICS; MONONUCLEAR CELL; NUCLEOTIDE SEQUENCE; SIMPLEXVIRUS; TRANSCRIPTION INITIATION; VIROLOGY; VIRUS ACTIVATION; VIRUS LATENCY; VIRUS REPLICATION;

BASE SEQUENCE; CELL CYCLE; CELL LINE; CELL PROLIFERATION; DNA-BINDING PROTEINS; GREEN FLUORESCENT PROTEINS; HIV INFECTIONS; HIV LONG TERMINAL REPEAT; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MOLECULAR SEQUENCE DATA; PROMOTER REGIONS, GENETIC; RECOMBINANT FUSION PROTEINS; SIMPLEXVIRUS; TRANSCRIPTIONAL ACTIVATION; VIRUS ACTIVATION; VIRUS LATENCY; VIRUS REPLICATION;

EID: 84937139658     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2014.0121     Document Type: Article

References (47)

1. Katlama C, Deeks SG, Autran B, et al.: Barriers to a cure for HIV: New ways to target and eradicate HIV-1 reservoirs. Lancet 2013;381(9883):2109-2117
2. Tyagi M and Bukrinsky M: Human immunodeficiency virus (HIV) latency: The major hurdle in HIV eradication. Mol Med 2012;18(1):1096
3. Iglesias-Ussel MD and Romerio F: HIV reservoirs: The new frontier. AIDS Rev 2011;13(1):13-29
4. Finzi D, Hermankova M, Pierson T, et al.: Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997;278(5341):1295-1300
5. Siliciano JD, Kajdas J, Finzi D, et al.: Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4 + T cells. Nat Med 2003;9(6):727-728
6. Shen L and Siliciano RF: Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection. J Allergy Clin Immun 2008; 122(1):22-28
7. Marsden MD and Zack JA: Eradication of HIV: Current challenges and new directions. J Antimicrob Chemother 2009;63(1):7-10
8. Richman DD, Margolis DM, Delaney M, et al.: The challenge of finding a cure for HIV infection. Science 2009; 323(5919):1304-1307
9. Barton KM, Burch BD, Soriano-Sarabia N, et al.: Prospects for treatment of latent HIV. Clin Pharmacol Ther 2012; 93(1):46-56
10. Kerr JS, Galloway S, Lagrutta A, et al.: Nonclinical safety assessment of the histone deacetylase inhibitor vorinostat. Int J Toxicol 2010;29(1):3-19
11. Matalon S, Rasmussen TA, and Dinarello CA: Histone deacetylase inhibitors for purging HIV-1 from the latent reservoir. Mol Med 2011;17(5-6):466
12. Pion M, Jordan A, Biancotto A, et al.: Transcriptional suppression of in vitro-integrated human immunodeficiency virus type 1 does not correlate with proviral DNA methylation. J Virol 2003;77(7):4025-4032
13. Miller JC, Tan S, Qiao G, et al.: A TALE nuclease architecture for efficient genome editing. Nat Biotechnol 2010; 29(2):143-148
14. Römer P, Hahn S, Jordan T, et al.: Plant pathogen recognition mediated by promoter activation of the pepper Bs3 resistance gene. Science 2007;318(5850):645-648
15. Kay S, Hahn S, Marois E, et al.: A bacterial effector acts as a plant transcription factor and induces a cell size regulator. Science 2007;318(5850):648-651
16. Bogdanove AJ, Schornack S, and Lahaye T: TAL effectors: Finding plant genes for disease and defense. Curr Opin Plant Biol 2010;13(4):394-401
17. Moscou MJ andBogdanoveAJ:Asimple cipher governsDNA recognition by TAL effectors. Science 2009;326(5959):1501
18. Scholze H and Boch J: TAL effector-DNA specificity. Virulence 2010;1(5):428-432
19. Boch J, Scholze H, Schornack S, et al.: Breaking the code of DNA binding specificity of TAL-type III effectors. Science 2009;326(5959):1509-1512
20. Bultmann S, Morbitzer R, Schmidt CS, et al.: Targeted transcriptional activation of silent oct4 pluripotency gene by combining designer TALEs and inhibition of epigenetic modifiers. Nucleic Acids Res 2012;40(12):5368-5377
21. Tremblay JP, Chapdelaine P, Coulombe Z, et al.: Transcription activator-like effector proteins induce the expression of the frataxin gene. Hum Gene Ther 2012;23(8):883-890
22. Zhang F, Cong L, Lodato S, et al.: Programmable sequence-specific transcriptional regulation of mammalian genome using designer TAL effectors. Nat Biotechnol 2011;29(2):149
23. Maeder ML, Linder SJ, Reyon D, et al.: Robust, synergistic regulation of human gene expression using TALE activators. Nat Methods 2013;10(3):243-245
24. Perez-Pinera P, Ousterout DG, Brunger JM, et al.: Synergistic and tunable human gene activation by combinations of synthetic transcription factors. Nat Methods 2013;10(3):239-242
25. Cermak T, Doyle EL, Christian M, et al.: Efficient design and assembly of custom TALEN and other TAL effectorbased constructs for DNA targeting. Nucleic Acids Res 2011;39(12):e82
26. Zhang F, Cong L, Lodato S, et al.: Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription. Nat Biotechnol 2011;29(2):149-153
27. Ding D, Qu X, Li L, et al.: Involvement of histone methyltransferase GLP in HIV-1 latency through catalysis of H3K9 dimethylation. Virology 2013;440(2):182-189
28. Qu X, Wang P, Ding D, et al.: Zinc-finger-nucleases mediate specific and efficient excision of HIV-1 proviral DNA from infected and latently infected human T cells. Nucleic Acids Res 2013;41(16):7771-7782
29. Ying H, Zhang Y, Zhou X, et al.: Selective histone deacetylase inhibitor M344 intervenes in HIV-1 latency through increasing histone acetylation and activation of NF-kappaB. PloS One 2012;7(11):e48832
30. Wang P, Qu X, Wang X, et al.: As2O3 synergistically reactivate latent HIV-1 by induction of NF-jB. Antiviral Res 2013;100(3):688-697
31. Jordan A, Defechereux P, and Verdin E: The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation. EMBO J 2001;20(7):1726-1738
32. Jordan A, Bisgrove D, and Verdin E: HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J 2003;22(8):1868-1877
33. Segal DJ, Gonçalves J, Eberhardy S, et al.: Attenuation of HIV-1 replication in primary human cells with a designed zinc finger transcription factor. J Biol Chem 2004;279(15): 14509-14519
34. Moscou MJ and Bogdanove AJ: A simple cipher governs DNA recognition by TAL effectors. Science 2009; 326(5959):1501
35. Eberhardy SR, Goncalves J, Coelho S, et al.: Inhibition of human immunodeficiency virus type 1 replication with artificial transcription factors targeting the highly conserved primer-binding site. J Virol 2006;80(6):2873-2883
36. Gaynor R: Regulation of HIV-1 gene expression by the transactivator protein Tat. Curr Top Microbiol 1995;193:51-77
37. Sakane N, Kwon H-S, Pagans S, et al.: Activation of HIV transcription by the viral Tat protein requires a demethylation step mediated by lysine-specific demethylase 1 (LSD1/KDM1). PLoS Pathog 2011;7(8):e1002184
38. Romani B, Engelbrecht S, and Glashoff RH: Functions of Tat: the versatile protein of human immunodeficiency virus type 1. J Gen Virol 2010;91(1):1-12
39. Marcello A, Zoppé M, and Giacca M: Multiple modes of transcriptional regulation by the HIV-1 Tat transactivator. IUBMB Life 2001;51(3):175-181
40. Ott M, Geyer M, and Zhou Q: The control of HIV transcription: Keeping RNA polymerase II on track. Cell Host Microbe 2011;10(5):426-435
41. Saksena NK and Potter SJ: Reservoirs of HIV-1 in vivo: Implications for antiretroviral therapy. AIDS Rev 2003; 5(1):3-18
42. Sarkar I, Hauber I, Hauber J, et al.: HIV-1 proviral DNA excision using an evolved recombinase. Science 2007; 316(5833):1912-1915
43. Ebina H, Misawa N, Kanemura Y, et al.: Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus. Sci Rep 2013;3:2510
44. Macías D, Oya R, Saniger L, et al.: A lentiviral vector that activates latent human immunodeficiency virus-1 proviruses by the overexpression of tat and that kills the infected cells. Hum Gene Ther 2009;20(11):1259-1268
45. Huelsmann PM, Hofmann AD, Knoepfel SA, et al.: A suicide gene approach using the human pro-apoptotic protein tBid inhibits HIV-1 replication. BMC Biotechnol 2011; 11(1):4
46. Wang P, Qu X, Wang X, et al.: Specific reactivation of latent HIV-1with designer zinc-finger transcription factors targeting the HIV-1 5-LTR promoter. Gene Ther 2014;21:491-495
47. Gräslund T, Magnenat L, Popkov M, et al.: Exploring strategies for the design of artificial transcription factors targeting sites proximal to known regulatory regions for the induction of c-globin expression and the treatment of sickle cell disease. J Biol Chem 2005;280:3707-3714